Avraham initiates ladostigil Stage 2 trial in MCI Avraham Pharmaceuticals Ltd snovitra 40 mg click here . Today the commencement of a Stage announced 2 clinical trial to judge the protection and efficacy of ladostigil in patients diagnosed with slight cognitive impairment . This 36-month, multi-center, randomized, double-blind, placebo-controlled trial shall include at least 200 sufferers in 16 centers in Europe and Israel. The Phase 2 research is a double-blind, closed-label, placebo-controlled trial occurring at 20 sites in five countries across European countries. In 2012 January, the Business performed an interim evaluation of this Stage 2 trial, which indicated that the medication is secure and well tolerated, in addition to shows a positive pattern toward efficacy.

Other articles from category "nutrition":

Random articles